Deucrictibant not checked
Pharvaris Netherlands B.V. · PHA-022121 · PHA121
FollowEvery change as it happens, and a Monday email
Trials
3 active
7 in total · 6 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use”In the company’s words, NCT07266805 on ClinicalTrials.gov
- Tested for
- Hereditary Angioedema (HAE) (2 trials), Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency and 10 more
- Main trialPhase 3
- “This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant soft capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.”In the company’s words, NCT07266805 on ClinicalTrials.gov
- Other names
- PHA-022121 · PHA121 · PHVS416
Other drugs for Hereditary Angioedema (HAE)
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- ADX-324ADARx Pharmaceuticals, Inc. · Phase 3
- BerotralstatBioCryst Pharmaceuticals · Phase 3
- NTLA-2002Intellia Therapeutics · Phase 3
- BW-20805Shanghai Argo Biopharmaceutical Co., Ltd. · Phase 2
Coming up3
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 19 Aug 2031Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovCompletion date moved: 2028-12 to 2031-08-19 · ClinicalTrials.gov NCT06679881
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2027 | Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | |
| Phase 3Enrolling by invitation | 19 Aug 2031 | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | |
| Phase 2/3Enrolling by invitation | Jun 2027 | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | |
| Phase 3Completed | 17 Oct 2025 | Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema | |
| Phase 3Completed | 21 Jul 2026 | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | |
| Phase 2Completed | 23 Sep 2022 | Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | |
| Phase 2Terminated | 30 Jun 2025 | Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026